Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User - Global Forecast to 2030

Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User - Global Forecast to 2030

Multiplex Assays Market by Type (Protein [Bead, Planar], Nucleic Acid, Cell) Technology (Flow Cytometry, PCR, Immunoassay) Application (R&D, Diagnosis (Oncology, Cardiovascular, Infectious, Autoimmune Diseases) Product, End User—Global Forecast to 2030

The global multiplex assays market is expected to reach $6.24 billion by 2030 at a CAGR of 9.0% from 2023 to 2030.

Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. The growth of this market is attributed to several factors, the advantages of multiplex assays over singleplex assays, the use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. However, the high costs of multiplex assay equipment restrain the growth of this market.

The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players operating in this market. However, the shortage of skilled professionals and the risk of cross-reactivity are major challenges to market growth.

Among all the types studied in this report, in 2023 protein multiplex assays segment is expected to account for the largest share of the multiplex assays market. Protein multiplex assays are further segmented into bead-based assays and planar assays. In 2023, the bead-based assays segment is expected to account for the largest share of the protein multiplex assays market. Multiplex bead-based assays have become essential tools for diagnosing various diseases. These assays are used for testing allergies, cancer markers, cytokines, cardiac markers, autoimmune diseases, and endocrine diseases. Bead-based assays offer a dynamic range of analytes as they are measured using flow cytometry. They are suitable for high-throughput analysis and are much more rapid, making them the preferred alternative to planar assays.

Among all the products studied in this report, in 2023, the consumables segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to the repetitive use of kits, the growing portfolio of disease-specific kits for early diagnosis of diseases, and the increasing product approvals. The continuous advancements in reagents and kits, the development of user-friendly diagnostic kits, and the adoption of multiplex assay kits in clinical and research laboratories positively impact the demand for consumables used in multiplex assays.

Among all the technologies studied in this report, the flow cytometry segment is projected to register the highest CAGR during the forecast period. Flow cytometry is considered an important tool in clinical diagnosis and research & development. It provides a multiparametric analysis of many single cells, which can be used in multiple research areas. Additionally, market players are launching advanced flow cytometers to support growing market needs. For instance, in June 2023, Becton, Dickinson and Company (U.S.) launched a BD FACSDuet to automate sample preparation during clinical flow cytometry diagnostics.

Among all the applications studied in this report, in 2023, the research & development segment is expected to account for the largest share of the multiplex assays market. The large market share of this segment is attributed to increasing applications of multiplex assays in drug discovery, biomarker profiling, and understanding disease mechanisms. The demand for multiplex assays in research & development is increasing rapidly and is also contributing to the largest share of the segment.

Among all the end users studied in this report, the research & development segment is expected to grow at the highest CAGR during the forecast period. The highest CAGR of this segment is attributed to factors such as the increasing R&D investments by pharmaceutical & biotechnology companies, the widespread utilization of multiplex assays in drug discovery & development, and a growing emphasis on personalized medicine research. The rising spending on R&D by pharmaceutical companies is also contributing to the largest share of this segment.

An in-depth analysis of the geographical scenario of the global multiplex assays market provides detailed qualitative and quantitative insights about the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2023, North America is expected to account for the largest share of the multiplex assays market, followed by Europe, Asia-Pacific, Latin America, and the Middle East & Africa. North America’s large share is attributed to the region’s high R&D spending by the pharmaceutical & biotechnology companies for the development of drugs and biomarker identification, increasing prevalence of chronic diseases, rising healthcare expenditure, presence of leading market players in the region, and favorable government initiatives for research & development. According to the U.S. Congressional Budget Office, U.S. pharmaceutical R&D expenditure increased from 91.1 billion in 2020 to 102.3 billion in 2021.

The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over the years (2020–2023). The key players operating in the global multiplex assays market are Thermo Fisher Scientific, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Seegene, Inc. (South Korea), Qiagen N.V. (Netherlands), PerkinElmer, Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Illumina, Inc. (U.S.), Becton, Dickinson and Company (U.S.), Quanterix Corporation (U.S.), DiaSorin S.p.A. (Italy), and Merck KGaA (Germany).

Scope of the Report:

Multiplex Assays Market Assessment, by Type

Protein Multiplex Assays
Bead-based Assays
Planar Assay
Nucleic Acid Multiplex Assays
Cell-based Multiplex Assays

Multiplex Assays Market Assessment, by Product

Consumables
Instruments
Software & Services

Multiplex Assays Market Assessment, by Technology

Flow Cytometry
Multiplex Immunoassay
Multiplex Real-Time PCR
Sequencing
Other Technologies

Note: Other technologies consist of microarray and immunohistochemistry

Multiplex Assays Market Assessment, by Application

Research & Development
Clinical Diagnosis
Infectious Diseases
Oncology
Cardiovascular Diseases
Autoimmune Diseases
Other Diseases

Note: Other diseases include neurological diseases, thrombosis, and drug abuse testing.

Multiplex Assays Market Assessment, by End User

Pharmaceutical & Biotechnology Companies
Diagnostic Laboratories
Hospitals
Other End Users

Note: Other end users consist of academic institutes & research centers, forensic labs, agriculture companies, and food & beverage companies

Multiplex Assays Market Assessment, by Geography

North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe (Roe)
Asia-Pacific (APAC)
China
Japan
India
Rest of Asia-Pacific (RoAPAC)
Latin America
Brazil
Mexico
Rest of Latin America (RoLATAM)
Middle East & Africa

Multiplex Assays Market - Report Summary

Report Metrics	Details
Years Considered	2021 - 2030
Base Year	2022
Forecast Period	2023-2030
Page Count	262
Units Referenced	Value (USD Million)
Segments/Key Topics	Market by Type, Product, Technology, Application, and End User
Regions Covered	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Key Companies Mentioned	Seegene, Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), DiaSorin S.p.A. (Italy), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Merck KGaA (Germany), and Quanterix Corporation (U.S.)

FAQs About the Report

What is the focus of the multiplex assays market?

The global multiplex assays market covers the study of various segments, including type, product, technology, application, and end-user at regional and country levels.

What is the value of revenue generated from multiplex assays across the globe?

The global multiplex assays market is projected to reach $6.24 billion by 2030 at a CAGR of 9.0% during the forecast period.

Which type segment is estimated to hold the major share of the market in 2023?

Among the types, the protein multiplex assays segment is estimated to hold a major market share in 2023. It is due to the increasing use of protein multiplex assays for the simultaneous detection of protein analytes. Protein multiplex assays are used to simultaneously detect chemokine, growth factors, cytokines, and others, which are the major factors for understanding the disease mechanism.

What are the key factors supporting the growth of this market? Also, what are the major opportunities for existing market players and new entrants in the global multiplex assays market?

The growth of this market is attributed to several factors, the advantages of multiplex assays over singleplex assays, the growing use of multiplexing in companion diagnostics, the increasing prevalence of chronic and infectious diseases, and rising awareness about the importance of early disease diagnosis. The growing need for high-throughput and automated laboratory systems and the increasing focus on personalized medicine is expected to generate growth opportunities for the players in this market.

Who are the major players operating in the global multiplex assays market?

The key players operating in the global multiplex assays market are Seegene, Inc. (South Korea), F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Becton, Dickinson and Company (U.S.), Bio-Rad Laboratories, Inc. (U.S.), DiaSorin S.p.A. (Italy), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Merck KGaA (Germany), and Quanterix Corporation (U.S.).

Which regions/countries are likely to offer significant growth opportunities for the vendors in this market during the analysis period?

The emerging countries in Asian-Pacific are projected to offer significant growth opportunities for the vendors in this market due to the advancing healthcare infrastructure, increasing research laboratories, and rising research funding in the healthcare & pharmaceutical industry.s